Size | Price | |
---|---|---|
100mg | ||
250mg | ||
500mg | ||
Other Sizes |
Targets |
MAO-A 0.004 ± 0. μM (IC50) 5-HT2A Receptor 0.014 μM (IC50) MAO-B 1.05 ± 0.0 μM (IC50)
|
---|---|
ln Vitro |
Compound I14, MAO-A/5-HT2AR-IN-1, has a noteworthy neurocytoprotective impact on the CORT-induced cell depression model at concentrations of 0–4 μM over a 24-hour period [1]. The active cavity of 5-HT2AR and MAO-A can be occupied by MAO-A/5-HT2AR-IN -1 through the use of numerous hydrogen bonding forces and π–π stacking interaction[1]. With regard to L02 cells (IC50 > 100 μM), SH-SY5Y (IC50 > 10 μM), and PC12 (IC50 > 10 μM), MAO-A/5-HT2AR-IN-1 shows minimal proliferation inhibitory actions, suggesting a good safety profile[1].
|
ln Vivo |
MAO-A/5-HT2AR-IN-1 (compound I14) at 10 and 20 mg/kg, dramatically improves mice's depressive-like behavior[1]. For seven days, MAO-A/5-HT2AR-IN-1 (0–1 μM) enhances the depression-like behavior and zebrafish locomotion[1]. The expression of 5-HT2AR in mouse brain tissue can be decreased and hippocampus neuronal cell injury can be repaired by MAO-A/5-HT2AR-IN-1[1]. A good clearance rate of 345.69 mL/min/kg has been reported for MAO-A/5-HT2AR-IN-1 in rats (2 mg/kg (iv) 10 mg/kg (ig); once)[1].
|
Cell Assay |
Cell Types: PC12 cells
Tested Concentrations: 4.0, 2.0, 1.0, and 0.5 μM (and 500 μM CORT) Incubation Duration: 24 h Experimental Results: demonstrated a significant protective effect on PC12 cells injury at different concentrations compared with the model group, where the best protective effect was observed at 0.5 μM . |
Animal Protocol |
Animal/Disease Models: ICR male mice (8−10 weeks old, weight 18-20 g)[1]
Doses: 10 mg/kg, 20 mg/kg Route of Administration: For 2 weeks Experimental Results: Dramatically improved depression-like behavior in mice, with the low dose group (10 mg/kg) being more potent than with the positive drug (Flu, 20 mg/kg). Had no relevant toxic effects on the liver, kidney, lung, and spleen of mice during the treatment period. Animal/Disease Models: Zebrafish (AB strain, Reserpine-induced zebrafish depression model)[1] Doses: 0.1, 0.5, 1 μM Route of Administration: Given 24 h after reserpine, for 7 days. Experimental Results: demonstrated that zebrafish in the I14 administered group moved Dramatically more distance, faster, and spent Dramatically more time in the upper part compared to the model group. Animal/Disease Models: SD (Sprague-Dawley) rats (male)[1] Doses: 2 mg/kg (iv) 10 mg/kg (ig) Route of Administration: IV, IG; once (pharmacokinetic/PK Analysis) Experimental Results: pharmacokinetic/PK Parameters of MAO-A/5-HT2AR-IN-1 in male SD (Sprague-Dawley) rats[1]. parameter 2 mg/kg (iv) 10 mg /kg (ig) Tm |
References |
[1]. Sun X, Li N, et al. Development of MAO-A and 5-HT2AR Dual Inhibitors with Improved Antidepressant Activity. J Med Chem. 2022 Oct 13;65(19):13385-13400.
|
Molecular Formula |
C30H28FN3O2
|
---|---|
Molecular Weight |
481.56
|
CAS # |
2769156-00-3
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
O=C1C2=CC=CC=C2C2N=CC=C3C=C(C=C1C=23)OCCCCN1CCN(C2C=CC=CC=2F)CC1
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.0766 mL | 10.3829 mL | 20.7658 mL | |
5 mM | 0.4153 mL | 2.0766 mL | 4.1532 mL | |
10 mM | 0.2077 mL | 1.0383 mL | 2.0766 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.